Aerie Pharmaceuticals Stock Forecast, Price & News

+0.06 (+0.39 %)
(As of 06/14/2021 02:01 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume5,648 shs
Average Volume607,221 shs
Market Capitalization$727.78 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AERI News and Ratings via Email

Sign-up to receive the latest news and ratings for Aerie Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Aerie Pharmaceuticals logo

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is also developing AR-15512 to treat signs and symptoms of dry eye; and AR-1105, AR-13503 SR, and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.72 out of 5 stars

Medical Sector

266th out of 2,099 stocks

Biological Products, Except Diagnostic Industry

35th out of 198 stocks

Analyst Opinion: 3.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions

Is Aerie Pharmaceuticals a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aerie Pharmaceuticals stock.
View analyst ratings for Aerie Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Aerie Pharmaceuticals?

Wall Street analysts have given Aerie Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aerie Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Aerie Pharmaceuticals' next earnings date?

Aerie Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Aerie Pharmaceuticals

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) released its quarterly earnings data on Tuesday, May, 4th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.69) by $0.03. The firm earned $22.97 million during the quarter, compared to analysts' expectations of $23.35 million. Aerie Pharmaceuticals had a negative trailing twelve-month return on equity of 337.04% and a negative net margin of 205.13%.
View Aerie Pharmaceuticals' earnings history

How has Aerie Pharmaceuticals' stock been impacted by COVID-19?

Aerie Pharmaceuticals' stock was trading at $14.55 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AERI stock has increased by 6.7% and is now trading at $15.52.
View which stocks have been most impacted by COVID-19

What price target have analysts set for AERI?

7 Wall Street analysts have issued 12-month price objectives for Aerie Pharmaceuticals' shares. Their forecasts range from $9.00 to $32.00. On average, they expect Aerie Pharmaceuticals' stock price to reach $24.14 in the next year. This suggests a possible upside of 55.6% from the stock's current price.
View analysts' price targets for Aerie Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Aerie Pharmaceuticals' key executives?

Aerie Pharmaceuticals' management team includes the following people:
  • Dr. Vicente J. Anido Jr., CEO & Chairman (Age 68, Pay $1.32M)
  • Mr. Thomas A. Mitro, Pres & COO (Age 63, Pay $747.68k)
  • Dr. Casey C. Kopczynski, Co-Founder & Chief Scientific Officer (Age 60, Pay $665.58k)
  • Mr. Richard James Rubino CPA, CFO, Sec. & Treasurer (Age 63, Pay $717.81k)
  • Mr. John W. LaRocca Esq., Gen. Counsel & Assistant Sec. (Age 56, Pay $658.86k)
  • Dr. David A. Hollander M.B.A., M.D., Chief R&D Officer (Age 47, Pay $648.77k)
  • Mr. Jeffrey Calabrese, Director of Accounting
  • Ms. Ami Bavishi, Director of Investor Relations
  • Mr. Tad Heitmann, Head of Communications
  • Evan Hockman, VP of Sales

Who are some of Aerie Pharmaceuticals' key competitors?

What other stocks do shareholders of Aerie Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include (CGC), Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Puma Biotechnology (PBYI), NVIDIA (NVDA), Wells Fargo & Company (WFC) and Alibaba Group (BABA).

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

Who are Aerie Pharmaceuticals' major shareholders?

Aerie Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Woodline Partners LP (4.60%), William Blair Investment Management LLC (3.49%), Schroder Investment Management Group (3.01%), Citigroup Inc. (2.50%), C WorldWide Group Holding A S (2.47%) and Fred Alger Management LLC (2.10%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski, Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino and Vicente Anido Jr.
View institutional ownership trends for Aerie Pharmaceuticals

Which institutional investors are selling Aerie Pharmaceuticals stock?

AERI stock was sold by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S, Granite Investment Partners LLC, State of Wisconsin Investment Board, DnB Asset Management AS, Millennium Management LLC, Citigroup Inc., Renaissance Technologies LLC, and Pinnacle Associates Ltd..
View insider buying and selling activity for Aerie Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Aerie Pharmaceuticals stock?

AERI stock was purchased by a variety of institutional investors in the last quarter, including Woodline Partners LP, Principal Financial Group Inc., Principal Financial Group Inc., Rubric Capital Management LP, Clearbridge Investments LLC, Levin Capital Strategies L.P., Integral Health Asset Management LLC, and William Blair Investment Management LLC. Company insiders that have bought Aerie Pharmaceuticals stock in the last two years include Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Richard J Rubino, and Vicente Anido Jr.
View insider buying and selling activity for Aerie Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Aerie Pharmaceuticals?

Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aerie Pharmaceuticals' stock price today?

One share of AERI stock can currently be purchased for approximately $15.52.

How much money does Aerie Pharmaceuticals make?

Aerie Pharmaceuticals has a market capitalization of $727.78 million and generates $83.14 million in revenue each year. The company earns $-183,100,000.00 in net income (profit) each year or ($3.12) on an earnings per share basis.

How many employees does Aerie Pharmaceuticals have?

Aerie Pharmaceuticals employs 365 workers across the globe.

What is Aerie Pharmaceuticals' official website?

The official website for Aerie Pharmaceuticals is

Where are Aerie Pharmaceuticals' headquarters?

Aerie Pharmaceuticals is headquartered at 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703.

How can I contact Aerie Pharmaceuticals?

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]

This page was last updated on 6/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.